Tem­pest seeks strate­gic al­ter­na­tives to fund Phase 3 liv­er can­cer tri­al

Tem­pest Ther­a­peu­tics is mulling its busi­ness op­tions, in­clud­ing po­ten­tial ex­it path­ways, af­ter an in­abil­i­ty to raise cash to bankroll its lead can­cer as­set through a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER